Current place of high-dose irinotecan chemotherapy in patients with metastatic colorectal cancer

Journal of Cancer Research and Clinical Oncology

Volumn 135, Issue 6, 2009, Pages 749-752

  Hebbar, Mohamed ^a   Ychou, Marc ^b   Ducreux, Michel ^c  

^a LILLE UNIVERSITY HOSPITAL   (France)

^b CENTRE VAL D AURELLE   (France)

^c INSTITUT GUSTAVE ROUSSY   (France)

Author keywords

Colorectal cancer; Irinotecan; Liver metastases; UGT1A1

Indexed keywords

7 ETHYL 10 HYDROXYCAMPTOTHECIN; BEVACIZUMAB; CETUXIMAB; FLUOROURACIL; FOLINIC ACID; GLUCURONOSYLTRANSFERASE 1A10; GRANULOCYTE COLONY STIMULATING FACTOR; IRINOTECAN; K RAS PROTEIN; LOPERAMIDE; OXALIPLATIN; RALTITREXED; SUNITINIB;

CANCER COMBINATION CHEMOTHERAPY; CANCER CONTROL; CANCER PATIENT; CANCER RESISTANCE; CLINICAL TRIAL; COLORECTAL CANCER; COLORECTAL CARCINOMA; DIARRHEA; DISEASE SEVERITY; DOSE RESPONSE; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG ELIMINATION; DRUG MEGADOSE; DRUG SAFETY; DRUG SUBSTITUTION; DRUG TOLERABILITY; DRUG TREATMENT FAILURE; DRUG WITHDRAWAL; FEBRILE NEUTROPENIA; FUNCTIONAL STATUS; GENE MUTATION; GENOTYPE; HIGH RISK PATIENT; HUMAN; LIVER FUNCTION; LIVER METASTASIS; MONOTHERAPY; MULTIPLE CYCLE TREATMENT; NEUTROPENIA; OUTCOME ASSESSMENT; PATIENT SELECTION; PRIORITY JOURNAL; RECOMMENDED DRUG DOSE; REVIEW; RISK BENEFIT ANALYSIS; TREATMENT RESPONSE; UNSPECIFIED SIDE EFFECT;

ANTINEOPLASTIC AGENTS, PHYTOGENIC; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CAMPTOTHECIN; COLORECTAL NEOPLASMS; DOSE-RESPONSE RELATIONSHIP, DRUG; GENOTYPE; GLUCURONOSYLTRANSFERASE; HUMANS; NEOPLASM METASTASIS; TREATMENT OUTCOME;

EID: 67349177047     PISSN: 01715216     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00432-009-0580-x     Document Type: Review

References (22)

1. D Abigerges GG Chabot JP Armand P Herait A Gouyette D Gandia 1995 Phase I and pharmacologic studies of the camptothecin analog irinotecan administered every 3 weeks in cancer patients J Clin Oncol 13 210 221
2. M Ando Y Hasegawa Y Ando 2005 Pharmacogenetics of irinotecan: a promoter polymorphism of UGT1A1 gene and severe adverse reactions to irinotecan Invest New Drugs 23 539 545 10.1007/s10637-005-4022-6
3. D Cunningham S Pyrrhonen RD James 1998 Randomised trial of irinotecan plus supportive care versus supportive care alone after fluorouracil failure for patients with metastatic colorectal cancer Lancet 352 1413 1418 10.1016/S0140-6736(98)02309-5
4. D Cunningham Y Humblet S Siena 2004 Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer N Engl J Med 351 337 345 10.1056/NEJMoa033025
5. F Di Fioré F Blanchard F Charbonnier 2007 Clinical relevance of KRAS mutation detection in metastatic colorectal cancer treated by Cetuximab plus chemotherapy Br J Cancer 96 1166 1169 10.1038/sj.bjc.6603685
6. Di Fioré F, Van Cutsem E, Laurent-Puig P, et al. (2008) Role of KRAS mutation in predicting response, progression-free survival, and overall survival in irinotecan-refractory patients treated with cetuximab plus irinotecan for a metastatic colorectal cancer: analysis of 281 individual data from published series. Proc am Soc Clin Oncol. J Clin Oncol 26(suppl):abstr 4035
7. JY Douillard D Cunningham AD Roth 2000 Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: a multicentre randomised trial Lancet 355 1041 1047 10.1016/S0140-6736(00)02034-1
8. M Ducreux M Ychou JF Seitz 1999 Irinotecan combined with bolus fluorouracil, continuous infusion fluorouracil, and high-dose leucovorin every two weeks (LV5FU2 regimen): a clinical dose-finding and pharmacokinetic study in patients with pretreated metastatic colorectal cancer J Clin Oncol 17 2901 2908
9. M Ducreux CH Köhne GK Schwartz U Vanhoefer 2003 Irinotecan in metastatic colorectal cancer: dose intensification and combination with new agents, including biological response modifiers Ann Oncol 14 Suppl 2 17 23 10.1093/annonc/mdg724
10. M Ducreux JL Raoul P Marti 2008 High-dose irinotecan plus LV5FU2 or simplified LV5FU (HD-FOLFIRI) for patients with untreated metastatic colorectal cancer: a new way to allow resection of liver metastases? Oncology 74 17 24 10.1159/000138352
11. J Duffour S Gourgou F Desseigne 2007 Multicentre phase II study using increasing doses of irinotecan combined with a simplified LV5FU2 regimen in metastatic colorectal cancer Cancer Chemother Pharmacol 60 383 389 10.1007/s00280-006-0372-9
12. RM Goldberg C Erlichman 1998 Irinotecan plus 5-FU and leucovorin in advanced colorectal cancer: North American trials Oncology 12 59 63
13. F Innocenti SD Undevia L Iyer 2004 Genetic variants in the UDP glucuronosyltransferase 1A1 gene predict the risk of severe neutropenia of irinotecan J Clin Oncol 22 1382 1388 10.1200/JCO.2004.07.173
14. A Lièvre JB Bachet V Boige 2008 KRAS mutations as an independent prognostic factor in patients with advanced colorectal cancer treated with cetuximab J Clin Oncol 26 374 379 10.1200/JCO.2007.12.5906
15. Y Merrouche JM Extra D Abigerges 1997 High dose-intensity of irinotecan administered every 3 weeks in advanced cancer patients: a feasibility study J Clin Oncol 15 1080 1086
16. Rivoire M, Thezenas S, Rebischung C, et al. (2008) Preliminary results of a randomized phase II trial comparing standard bi-therapy versus three intensified chemotherapy regimens as treatment for patients with non resectable liver metastases from colorectal cancer (METHEP). Proc Am Soc Clin Oncol. J Clin Oncol 26(suppl):absr 4075
17. Roth AD, Yan P, Dietrich D, et al. (2008) Is UGT1A1*28 homozygosity the strongest predictor for severe hematotoxicity in patients treated with 5-fluorouracil-irinotecan? Results of the PETACC 3 - EORTC 40993 -SAKK 60/00 trial comparing IRI/5-FU/folinic acid to 5-FU/FA in stage II-III colon cancer patients. Proc Am Soc Clin Oncol. J Clin Oncol 26(suppl):abstr 4036
18. P Rougier E Van Cutsem E Bajetta 1998 Randomised trial of irinotecan versus fluorouracil by continuous infusion after fluorouracil failure in patients with metastatic colorectal cancer Lancet 352 1407 1412 10.1016/S0140-6736(98)03085-2
19. LB Saltz JV Cox C Blanke 2000 Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer Irinotecan Study Group N Engl J Med 343 905 914 10.1056/NEJM200009283431302
20. E Van Cutsem L Dirix JL Van Laethem 2005 Optimisation of irinotecan dose in the treatment of patients with metastatic colorectal cancer after 5-FU failure: results from a multinational, randomised phase II study Br J Cancer 92 1055 1062 10.1038/sj.bjc.6602462
21. Van Cutsem E, Lang I, D'Haens G, et al. (2008) KRAS status and efficacy in the first-line treatment of patients with metastatic colorectal cancer treated with FOLFIRI with or without cetuximab: the CRYSTAL experience. Proc Am Soc Clin Oncol. J Clin Oncol 26(suppl):abstr 2
22. M Ychou JL Raoul F Desseigne 2002 High-dose, single-agent irinotecan as first-line therapy in the treatment of metastatic colorectal cancer Cancer Chemother Pharmacol 50 383 391 10.1007/s00280-002-0506-7